Table of Contents Author Guidelines Submit a Manuscript
Pathology Research International
Volume 2017 (2017), Article ID 6794150, 7 pages
https://doi.org/10.1155/2017/6794150
Research Article

Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas

1Urology Department, Interbalkan Medical Center, Thessaloniki, Greece
2Pathology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
3Laboratory of Biochemistry, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece
4Urology Department, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece
5Laboratory of Histology-Embryology, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece

Correspondence should be addressed to Triantafyllia Koletsa

Received 30 October 2016; Accepted 29 December 2016; Published 22 January 2017

Academic Editor: Marco Volante

Copyright © 2017 Nikolaos Koletsas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Bolenz, S. F. Shariat, P. I. Karakiewicz et al., “Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder,” BJU International, vol. 106, no. 8, pp. 1216–1222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. N.-H. Chow, H.-S. Liu, E. I. C. Lee et al., “Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer,” Anticancer Research, vol. 17, no. 2B, pp. 1293–1296, 1997. View at Google Scholar · View at Scopus
  3. M. Enache, C. E. Simionescu, and A. Stepan, “EGFR and Her2/neu immunoexpression in papillary urothelial bladder carcinomas,” Romanian Journal of Morphology and Embryology, vol. 54, no. 1, pp. 137–141, 2013. View at Google Scholar · View at Scopus
  4. P. Korkolopoulou, G. Levidou, E.-A. Trigka et al., “A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma,” BJU International, vol. 110, no. 11, pp. E1237–E1348, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Campiglio, S. Ali, P. G. Knyazev, and A. Ullrich, “Characteristics of EGFR family-mediated HRG signals in human ovarian cancer,” Journal of Cellular Biochemistry, vol. 73, no. 4, pp. 522–532, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. N. V. Sergina, M. Rausch, D. Wang et al., “Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3,” Nature, vol. 445, no. 7126, pp. 437–441, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. P. Soltoff, K. L. Carraway III, S. A. Prigent, W. G. Gullick, and L. C. Cantley, “ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor,” Molecular and Cellular Biology, vol. 14, no. 6, pp. 3550–3558, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. R. J. Shaw and L. C. Cantley, “Ras, PI(3)K and mTOR signalling controls tumour cell growth,” Nature, vol. 441, no. 7092, pp. 424–430, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. K. D. Courtney, R. B. Corcoran, and J. A. Engelman, “The PI3K pathway as drug target in human cancer,” Journal of Clinical Oncology, vol. 28, no. 6, pp. 1075–1083, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Bartholomeusz and A. M. Gonzalez-Angulo, “Targeting the PI3K signaling pathway in cancer therapy,” Expert Opinion on Therapeutic Targets, vol. 16, no. 1, pp. 121–130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Pópulo, J. M. Lopes, and P. Soares, “The mTOR signalling pathway in human cancer,” International Journal of Molecular Sciences, vol. 13, no. 2, pp. 1886–1918, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Knowles, F. M. Platt, R. L. Ross, and C. D. Hurst, “Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer,” Cancer and Metastasis Reviews, vol. 28, no. 3-4, pp. 305–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Askham, F. Platt, P. A. Chambers, H. Snowden, C. F. Taylor, and M. A. Knowles, “AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K,” Oncogene, vol. 29, no. 1, pp. 150–155, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Burger, W. Oosterlinck, B. Konety et al., “ICUD-EAU international consultation on bladder cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder,” European Urology, vol. 63, no. 1, pp. 36–44, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Z. Millis, D. Bryant, G. Basu et al., “Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin,” Clinical Genitourinary Cancer, vol. 13, no. 1, pp. e37–e49, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Sun and G. A. Herrera, “E-cadherin expression in invasive urothelial carcinoma,” Annals of Diagnostic Pathology, vol. 8, no. 1, pp. 17–22, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. A. C. Wolff, M. E. Hammond, D. G. Hicks et al., “American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update,” Journal of Clinical Oncology, vol. 31, no. 31, pp. 3997–4013, 2013. View at Publisher · View at Google Scholar
  18. S. Leibl, R. Zigeuner, G. Hutterer, T. Chromecki, P. Rehak, and C. Langner, “EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology,” Acta Pathologica, Microbiologica, et Immunologica Scandinavica, vol. 116, no. 1, pp. 27–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. N. D. Gonzalez-Roibon, A. Chaux, T. Al-Hussain et al., “Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder,” Human Pathology, vol. 44, no. 4, pp. 612–622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Afonso, A. Longatto-Filho, V. M. Da Silva, T. Amaro, and L. L. Santos, “Phospho-mTOR in non-tumour and tumour bladder urothelium: pattern of expression and impact on urothelial bladder cancer patients,” Oncology Letters, vol. 8, no. 4, pp. 1447–1454, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. S. T. dos Reis, K. R. M. Leite, A. M. Neto et al., “Immune expression of E-cadherin and α, β and γ-catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas,” International Braz J Urol, vol. 38, no. 4, pp. 466–473, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Kaptain, L. K. Tan, and B. Chen, “Her-2/neu and breast cancer,” Diagnostic Molecular Pathology, vol. 10, no. 3, pp. 139–152, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. D. A. Pigott, A. J. Proctor, M. E. Eydmann et al., “Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder,” British Journal of Cancer, vol. 63, no. 4, pp. 601–608, 1991. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Wülfing, D. Von Struensee, S. Bierer, M. Bögemann, L. Hertle, and E. Eltze, “ExpressIon of her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy,” Aktuelle Urologie, vol. 36, no. 5, pp. 423–429, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Laé, J. Couturier, S. Oudard, F. Radvanyi, P. Beuzeboc, and A. Vieillefond, “Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients,” Annals of Oncology, vol. 21, no. 4, pp. 815–819, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. S. Ross, J. A. Fletcher, K. J. Bloom et al., “Targeted therapy in breast cancer: the HER-2/neu gene and protein,” Molecular & Cellular Proteomics, vol. 3, no. 4, pp. 379–398, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Albarello, L. Pecciarini, and C. Doglioni, “HER2 testing in gastric cancer,” Advances in Anatomic Pathology, vol. 18, no. 1, pp. 53–59, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. F. De Vita, F. Giuliani, N. Silvestris, G. Catalano, F. Ciardiello, and M. Orditura, “Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target,” Cancer Treatment Reviews, vol. 36, no. 3, pp. S11–S15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Krüger, G. Weitsch, H. Büttner et al., “HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications,” International Journal of Cancer, vol. 102, no. 5, pp. 514–518, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Alexa, F. Baderca, D. E. Zăhoi, R. Lighezan, D. Izvernariu, and M. Raica, “Clinical significance of Her2/neu overexpression in urothelial carcinomas,” Romanian Journal of Morphology and Embryology, vol. 51, no. 2, pp. 277–282, 2010. View at Google Scholar · View at Scopus
  31. P. H. Abbosh, D. J. McConkey, and E. R. Plimack, “Targeting signaling transduction pathways in bladder cancer,” Current Oncology Reports, vol. 17, no. 12, article 58, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Tsuruta, H. Kishimoto, T. Sasaki et al., “Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients,” Cancer Research, vol. 66, no. 17, pp. 8389–8396, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. F. M. Platt, C. D. Hurst, C. F. Taylor, W. M. Gregory, P. Harnden, and M. A. Knowles, “Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer,” Clinical Cancer Research, vol. 15, no. 19, pp. 6008–6017, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Schultz, R. Albadine, J. Hicks et al., “Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy,” Cancer, vol. 116, no. 23, pp. 5517–5526, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Cordon-Cardo, “Molecular alterations associated with bladder cancer initiation and progression,” Scandinavian Journal of Urology and Nephrology, vol. 42, no. 218, pp. 154–165, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Tian and J. I. Epstein, “Invasive low-grade papillary urothelial carcinoma: an immunohistochemical study of 26 cases,” Human Pathology, vol. 46, no. 12, pp. 1836–1841, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Castillo-Martin, J. Domingo-Domenech, O. Karni-Schmidt, T. Matos, and C. Cordon-Cardo, “Molecular pathways of urothelial development and bladder tumorigenesis,” Urologic Oncology: Seminars and Original Investigations, vol. 28, no. 4, pp. 401–408, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Houédé and P. Pourquier, “Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers,” Pharmacology & Therapeutics, vol. 145, pp. 1–18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Ahmad, J. P. Morton, L. B. Singh et al., “β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation,” Oncogene, vol. 30, no. 2, pp. 178–189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. M. Puzio-Kuter, M. Castillo-Martin, C. W. Kinkade et al., “Inactivation of p53 and Pten promotes invasive bladder cancer,” Genes & Development, vol. 23, no. 6, pp. 675–680, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Fechner, K. Claßen, D. Schmidt, S. Hauser, and S. C. Müller, “apamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer,” Urology, vol. 73, no. 3, pp. 665–668, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. J. J. Mansure, R. Nassim, S. Chevalier, J. Rocha, E. Scarlata, and W. Kassouf, “Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer,” Cancer Biology and Therapy, vol. 8, no. 24, pp. 2339–2347, 2009. View at Google Scholar · View at Scopus
  43. B. Markman, R. Dienstmann, and J. Tabernero, “Targeting the PI3K/Akt/mTOR pathway–beyond rapalogs,” Oncotarget, vol. 1, no. 7, pp. 530–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Seront, A. Pinto, C. Bouzin, L. Bertrand, J.-P. Machiels, and O. Feron, “PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation,” British Journal of Cancer, vol. 109, no. 6, pp. 1586–1592, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Bagrodia, L.-M. Krabbe, B. A. Gayed et al., “Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma,” Urology, vol. 84, no. 5, pp. 1134–1140, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. R. T. Bryan, “Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena,” Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences, vol. 370, no. 1661, Article ID 20140042, 2015. View at Publisher · View at Google Scholar · View at Scopus